DNTH312 Is Not the Story — Claseprubart Is: What Dianthus Is Actually Worth

Dianthus Therapeutics dropped a press release on August 4th unveiling DNTH312, a "first-in-class" dual-target autoimmune drug, and the headlines treated it like a breakthrough. In an ironic move, the company that already has a Phase 3 trial in the pipeline gets the most attention for a molecule that won't reach human testing until year-end 2027. The market is focused on the wrong variable.

The narrative says DNTH312 is a game changer. The math says the actual thesis rests on claseprubart, a drug that already has data, a Phase 3 readout coming by the end of this year, and a 75% interim response rate that has sent the stock to a $6.09 billion market cap. DNTH312 is optionality. Claseprubart is the bet.

Here's what the numbers actually show.

1. DNTH312 is preclinical — with zero human data and 18 months until Phase 1.

DNTH312 combines claseprubart's active C1s (aC1s) inhibition with BAFF/APRIL targeting in a single bifunctional fusion protein. In lay terms: it blocks the complement cascade downstream, where inflammation damages tissue, while also hitting B-cell survival signals upstream, where the autoantibodies are produced. The dual mechanism is clever. It also means the molecule has never been tested in a human being.

Dianthus aims for Phase 1 readiness by year-end 2027. The company reported comparable in vitro potency to claseprubart and a 22-day half-life in non-human primates, alongside IgM, IgA, and IgG reduction similar to povetacicept — a late-stage BAFF/APRIL inhibitor. Those are encouraging bench results. They are not a thesis.

The new intellectual property extends through at least 2047, well beyond claseprubart's expected protection through 2043. That's useful franchise life. It doesn't change the timeline.

2. Claseprubart's Phase 3 CAPTIVATE trial in CIDP is the near-term catalyst — and the interim data is strong.

This is the variable that matters. The CAPTIVATE trial's Part A was an open-label dose-finding study targeting a 50% response rate (at least 20 confirmed responders out of 40 participants). Dianthus hit that bar early, before all 40 participants completed, and the full interim analysis showed a 75% response rate. That's the kind of signal that pushes a biotech stock higher. It's also why the stock surged over 800% over the past year.

Part B — the randomized, placebo-controlled segment that regulators actually care about — has top-line results expected by year-end 2026. That's roughly five months away. The FDA has already agreed to remove anti-nuclear antibody screening and routine testing from the trial protocol, reclassifying the theoretical risk of drug-induced lupus, which clears a regulatory speed bump. No serious infections, no drug-induced lupus cases, and no safety-related discontinuations have occurred to date.

This is the event that either validates the $6 billion valuation or exposes it as premature.

3. The burn rate matters more than the press release.

Dianthus held approximately $1.2 billion in cash, cash equivalents, and investments as of June 30, 2026. That's a comfortable runway, projected into 2030. But it came at a cost: a $625 million equity raise in March 2026 at $81 per share, adding over 7.7 million shares to the float. That dilution was priced in when it happened.

Q2 2026 saw a net loss of $50.2 million ($0.90 per share), with R&D expenses at $48.7 million and G&A at $13.6 million. Full-year 2025 burned $162.3 million. Revenue was $1.2 million over the first half of 2026, all from licensing — essentially zero. The company is spending roughly $50 million per quarter and generating no commercial income.

At a $6.09 billion market cap and $4.9 billion enterprise value (market cap net of cash), the stock prices in not just success but a best-in-class franchise with commercial scale across multiple indications. For a company losing $150–160 million annually with its first Phase 3 readout five months away, that's a lot of conviction to ask for.

4. The pipeline depth is real but doesn't change the near-term math.

Beyond claseprubart and DNTH312, Dianthus is developing DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL for Sjögren's disease, systemic lupus, and dermatomyositis. Phase 1 healthy volunteer data from China is expected by year-end 2026. The Phase 2 MMN trial (MoMeNtum) for claseprubart has completed enrollment with 46 patients and expects top-line results in December 2026.

These programs add optionality. They don't change the fact that the stock's trajectory hinges on CAPTIVATE Part B.

5. The competitor landscape is crowded, and DNTH312 isn't the first mover.

BAFF/APRIL inhibitors are a well-trodden path. Telitacicept (Remegen/Vor Bio) has already secured a $125 million licensing deal. Povetacicept is in late-stage trials. Complement inhibition is equally competitive — Apellis, Roche, and Iveric Bio all have complement-targeted programs at various stages. DNTH312's bifunctional approach is novel, but novelty without clinical data is a thesis waiting to prove itself, not one that's proven.

The disconnect.

The stock trades at roughly $109, with analyst Rami Katkhuda maintaining a Buy rating and a $125 price target after the DNTH312 announcement. Wall Street is reacting to the headline rather than the timeline. The $6 billion market cap assumes claseprubart wins big in CIDP, expands into gMG and MMN, and that DNTH312 becomes a franchise extender — all before generating meaningful revenue.

That's not a false narrative. It's an optimistic one that hasn't been tested yet. The 75% interim response rate supports the bullish case. The FDA's cooperation supports it. The $1.2 billion cash runway supports it by removing the dilution overhang for now.

But the gap between $6 billion in market value and $1.2 million in semiannual revenue is a gap that needs closing. The catalyst is CAPTIVATE Part B. If the controlled trial confirms the 75% response rate, the valuation has a foundation. If it underperforms, the stock has very little to fall back on — DNTH312 won't be in humans for 18 months, and the gMG Phase 3 doesn't report until the second half of 2028.

The break condition.

This stock appears to have a clear binary event on deck. CAPTIVATE Part B at year-end 2026 is the milestone that either validates the current market cap or forces a reckoning. The bull case is defensible: claseprubart's interim data is strong, the cash position removes near-term execution risk, and the pipeline depth gives the company optionality beyond CIDP.

The key risk is that the controlled trial doesn't replicate the open-label signal, or that the response rate drops enough to undermine best-in-class positioning. At $4.9 billion in enterprise value, the market is pricing in a lot of success for a company that loses $50 million a quarter. If CAPTIVATE confirms the thesis, the valuation may look like a major bargain. If it doesn't, the stock could see a sharp repricing.

The narrative around DNTH312 is interesting science. The investment case is whether claseprubart delivers on the promise Wall Street has already paid for.